The Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP), a national program out of VCU Massey Comprehensive ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ: GILD) ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 15 years ago, it would be worth $681.19 today based on a price of $112.09 for GILD at the time of writing.

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effec ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...